GEN Exclusives

More »

GEN News Highlights

More »
Sep 23, 2010

NCI Awarded Advanced Targeting Systems $3M to Advance Preclinical Cancer Pain Candidate

  • Advanced Targeting Systems received $3 million from the NCI to advance SP-SAP over the next two years into clinical trials for cancer pain. SP-SAP is a conjugate between the pain-processing peptide substance P and the ribosome-inactivating protein saporin.

    The mechanism of action of SP-SAP is well characterized, a rarity in pain therapeutics, according to Advanced Targeting Systems. A small number of cells that process pathological pain signals is removed, causing relief that appears to be permanent, the firm explains. Normal acute pain is unaffected.

    FDA recommended that the first population to undergo treatment with SP-SAP is terminal cancer patients who are resistant to opioids such as morphine. In preclinical tests, a single treatment with SP-SAP alleviated pathologic pain perception without affecting other sensory signal pathways.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Mindclones and Immortality

Is the idea of making a software copy of a human mind something in the realm of reality or science fiction?